Aneurysm study of pipeline in an observational registry (ASPIRe)

David F. Kallmes, Waleed Brinjikji, Edoardo Boccardi, Elisa Ciceri, Orlando Diaz, Rabih Tawk, Henry Woo, Pascal Jabbour, Felipe Albuquerque, Rene Chapot, Alain Bonafe, Shervin R. Dashti, Josser E.Delgado Almandoz, Curtis Given Ii, Michael E. Kelly, De Witte T.Cross Iii, Gary Duckwiler, Nasser Razack, Ciaran J. Powers, Sebastian FischerDemetrius Lopes, Mark R. Harrigan, Daniel Huddle, Raymond Turner Iv, Osama O. Zaidat, Luc Defreyne, Vitor Mendes Pereira, Saruhan Cekirge, David Fiorella, Ricardo A. Hanel, Pedro Lylyk, Cameron Mcdougall, Adnan Siddiqui, Istvan Szikora, Elad Levy

Research output: Contribution to journalArticlepeer-review

95 Scopus citations


Background and Objective: Few prospective studies exist evaluating the safety and efficacy of the Pipeline Embolization Device (PED) in the treatment of intracranial aneurysms. The Aneurysm Study of Pipeline In an observational Registry (ASPIRe) study prospectively analyzed rates of complete aneurysm occlusion and neurologic adverse events following PED treatment of intracranial aneurysms. Materials and Methods: We performed a multicenter study prospectively evaluating patients with unruptured intracranial aneurysms treated with PED. Primary outcomes included (1) spontaneous rupture of the Pipeline-treated aneurysm; (2) spontaneous nonaneurysmal intracranial hemorrhage (ICH); (3) acute ischemic stroke; (4) parent artery stenosis, and (5) permanent cranial neuropathy. Secondary endpoints were (1) treatment success and (2) morbidity and mortality at the 6-month follow-up. Vascular imaging was evaluated at an independent core laboratory. Results: One hundred and ninety-one patients with 207 treated aneurysms were included in this registry. The mean aneurysm size was 14.5 ± 6.9 mm, and the median imaging follow-up was 7.8 months. Twenty-four aneurysms (11.6%) were small, 162 (78.3%) were large and 21 (10.1%) were giant. The median clinical follow-up time was 6.2 months. The neurological morbidity rate was 6.8% (13/191), and the neurological mortality rate was 1.6% (3/191). The combined neurological morbidity/mortality rate was 6.8% (13/191). The most common adverse events were ischemic stroke (4.7%, 9/191) and spontaneous ICH (3.7%, 7/191). The complete occlusion rate at the last follow-up was 74.8% (77/103). Conclusions: Our prospective postmarket study confirms that PED treatment of aneurysms in a heterogeneous patient population is safe with low rates of neurological morbidity and mortality. Patients with angiographic follow-up had complete occlusion rates of 75% at 8 months.

Original languageEnglish (US)
Pages (from-to)89-99
Number of pages11
JournalInterventional Neurology
Issue number1-2
StatePublished - Jun 14 2016


  • Flow diverter
  • Intracranial aneurysm
  • Neurological morbidity and mortality

ASJC Scopus subject areas

  • Surgery
  • Clinical Neurology
  • Cardiology and Cardiovascular Medicine


Dive into the research topics of 'Aneurysm study of pipeline in an observational registry (ASPIRe)'. Together they form a unique fingerprint.

Cite this